查看2017.HSA.doxorubicin.AC.vs.ADTIC的源代码
←
2017.HSA.doxorubicin.AC.vs.ADTIC
跳转到:
导航
,
搜索
因为以下原因,你没有权限编辑本页:
您刚才请求的操作只有这个用户组中的用户才能使用:
用户
您可以查看并复制此页面的源代码:
=== 临床结果 (Clinical outcomes) === 第 1 组的 18 只狗中有 13 只 (72.2%) 在中位 89 天(范围:44-188 天)后出现转移性疾病。在肝脏(n=7)、肺(n=3)、腹膜(n=2)、肝脏和肺(n=1)中发现转移。两只腹膜转移的狗出现了腹腔血肿。第 2 组的 9 只狗中有 1 只 (11.1%) 在 378 天后发生肺转移。在就诊时已经发生转移的三只狗中,有两只分别在 48 天和 70 天后记录了疾病进展。在这些狗中,分别在肺(n = 1),肾脏和肝脏(n = 1)中发现了转移。总体而言,与接受 AC 的狗相比,接受 ADTIC 的狗使用 Kaplan-Meier 产品限值计算的中位 TTM 显着更长(分别为 >550 天和 112 天;P =0.021;图1)。第 1 组中包括 18 只狗的 16 只 (88.8%) 在研究结束时死亡:15 只 (83.3%) 因 HSA 进展而死亡,中位生存时间为 140 天(范围:37-301 天),而一只狗在 158 天后死亡,原因是 Thirteen (72.2%) of the eighteen dogs in group 1 developed metastatic disease after a median of 89 days (range: 44–188 days). Metastases were found in the liver (n=7), lungs (n=3), peritoneum (n=2), liver and lungs (n=1). The two dogs with metastases to the peritoneum developed haemoabdomen. One (11.1%) of the nine dogs included in group 2 developed pulmonary metastasis after 378 days. Of the three dogs already having metastasis at presentation, two had disease progression documented after 48 and 70 days, respectively. In these dogs, metastases were found in the lungs (n=1), kidney and liver (n=1), respectively. Overall, median TTM as calculated with Kaplan–Meier product limit was significantly longer for dogs receiving ADTIC compared with those receiving AC (>550 days versus 112 days, respectively; P =0.021; Fig. 1). Sixteen (88.8%) of the eighteen dogs included in group 1 died by the end of the study: 15 (83.3%) died as a result of HSA progression with a median survival time of 140 days (range: 37–301 days), whereas one dog died after 158 days because of 胃扩张-扭转,无肿瘤复发或转移的证据。两只患有脾 II 期 HSA 的狗在诊断后分别存活 85 天和 262 天。第 2 组的 9 只狗中有 7 只 (77.7%) 在研究结束时死亡:4 只 (44.4%) 因 HSA 进展而死亡,中位生存时间为 106 天(范围:74-480 天)。在这四只狗中,三只患有脾脏 III 期 HSA,一只患有肾脏 II 期 HSA。其余3例(脾II.期HSA)在诊断后803天因胃扩张-扭转死亡,1例(脾II.期HSA)960天后死于晚期慢性肾病[国际肾脏协会(IRIS)IV期],1例(肠系膜II.期HSA)在1230天后死于转移性肥大细胞瘤。两只患有皮下 II 期 HSA 的狗在诊断后 572 天和 1260 天仍然活着。总体而言,接受ADTIC的狗的中位生存期明显长于接受AC的狗(分别为>550天和142天;P =0.011;图2)。在第 1 组中,没有一只狗在诊断后 1 年存活,而在第 2 组中,1 年和 1.5 年生存率分别为 66.8% 和 55.8% gastric dilatation-volvulus with no evidence of tumour recurrence or metastasis. Two dogs with splenic stage II HSA were still alive, 85 and 262 days after the diagnosis, respectively. Seven (77.7%) of the nine dogs in group 2 died by the end of the study: four (44.4%) died as a result of HSA progression with a median survival time of 106 days (range: 74–480 days). Of these four dogs, three had splenic stage III HSA and one had renal stage II HSA. Regarding the remaining three, one of them (splenic stage II HSA) died 803 days after the diagnosis owing to gastric dilatation-volvulus, one (splenic stage II HSA) died after 960 days owing to advanced chronic kidney disease [international renal interest society (IRIS) stage IV] and one (mesenteric stage II HSA) died after 1230 days owing to a metastatic mast cell tumour. Two dogs with subcutaneous stage II HSA were still alive, 572 and 1260 days after the diagnosis. Overall, dogs receiving ADTIC had significantly longer median survival than those receiving AC (>550 days versus 142 days, respectively; P =0.011; Fig. 2). In group 1 none of the dogs was alive at 1 year after diagnosis, whereas in group 2 the 1- and 1.5-year survival rates were 66.8 and 55.8%, respectively <br>
返回到
2017.HSA.doxorubicin.AC.vs.ADTIC
。
个人工具
登录
名字空间
页面
讨论
变换
查看
阅读
查看源代码
查看历史
操作
搜索
导航
首页
社区专页
新闻动态
最近更改
随机页面
帮助
工具箱
链入页面
相关更改
特殊页面